EQL — EQL Pharma AB Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesSpeculativeSmall CapNeutral

Annual income statement for EQL Pharma AB, fiscal year end - March 31st, SEK millions except per share, conversion factor applied.

	R2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	SAS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	179	410	260	264	374
Cost of Revenue
Gross Profit	51	95.7	116	115	156
Selling / General / Administrative Expenses
Research And Development
Other Operating Expenses
Total Operating Expenses	168	371	219	232	306
Operating Profit	11.5	38.8	41.3	32.6	67.4
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	10.4	36	39	28.6	54.4
Provision for Income Taxes
Net Income After Taxes	10.4	31.5	30.9	22.7	43.1
Net Income Before Extraordinary Items
Net Income	10.4	31.5	30.9	22.7	43.1
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	10.4	31.5	30.9	22.7	43.1
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.357	1.09	1.05	0.781	1.48
Dividends per Share